Skip to content
10-Q

Quarterly Report

Citius Pharmaceuticals, Inc. CTXR

0001213900-25-074997

← back to feed
Filed
Aug 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Aug 11, 2025 17.01M sh
Shares Diluted Q3 2025 · Jun 30, 2025 11.01M sh
Shares Diluted Q3 2025 · Jun 30, 2025 9.02M sh
Shares Diluted restated Q3 2025 · Jun 30, 2024 6.95M sh
Shares Diluted restated Q3 2025 · Jun 30, 2024 6.56M sh
Operating Cash Flow Q3 2025 · Jun 30, 2025 −$14.67M
Operating Cash Flow Q3 2025 · Jun 30, 2024 −$22.29M
Cash And Equivalents Q3 2025 · Jun 30, 2025 $6.09M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $3.25M
Stockholders Equity Q3 2025 · Jun 30, 2025 $65.06M
Stockholders Equity Q3 2025 · Sep 30, 2024 $70.08M
Current Liabilities Q3 2025 · Jun 30, 2025 $51.84M
Current Liabilities Q3 2025 · Sep 30, 2024 $35.81M
Total Liabilities Q3 2025 · Jun 30, 2025 $60.12M
Total Liabilities Q3 2025 · Sep 30, 2024 $42.55M
Current Assets Q3 2025 · Jun 30, 2025 $24.61M
Current Assets Q3 2025 · Sep 30, 2024 $14.22M
Total Assets Q3 2025 · Jun 30, 2025 $127.68M
Total Assets Q3 2025 · Sep 30, 2024 $116.65M
Eps Diluted Q3 2025 · Jun 30, 2025 −$0.80
Eps Diluted Q3 2025 · Jun 30, 2025 −$3.27
Eps Diluted Q3 2025 · Jun 30, 2024 −$1.57
Eps Diluted Q3 2025 · Jun 30, 2024 −$4.37
Eps Basic Q3 2025 · Jun 30, 2025 −$0.80
Eps Basic Q3 2025 · Jun 30, 2025 −$3.27
Eps Basic Q3 2025 · Jun 30, 2024 −$1.57
Eps Basic Q3 2025 · Jun 30, 2024 −$4.37
Sga Expense Q3 2025 · Jun 30, 2025 $4.45M
Sga Expense Q3 2025 · Jun 30, 2025 $14.63M
Sga Expense Q3 2025 · Jun 30, 2024 $4.81M
Sga Expense Q3 2025 · Jun 30, 2024 $12.76M
Rd Expense Q3 2025 · Jun 30, 2025 $1.62M
Rd Expense Q3 2025 · Jun 30, 2025 $7.51M
Rd Expense Q3 2025 · Aug 31, 2024 $33.4M
Rd Expense Q3 2025 · Jun 30, 2024 $2.76M
Rd Expense Q3 2025 · Jun 30, 2024 $8.99M
Operating Income Q3 2025 · Jun 30, 2025 −$8.79M
Operating Income Q3 2025 · Jun 30, 2025 −$30.09M
Operating Income Q3 2025 · Jun 30, 2024 −$10.63M
Operating Income Q3 2025 · Jun 30, 2024 −$30.95M